May 31, 2019 08:20 AM EDT

Aslan doubles down on CSL drug, plots longshot rivalry with Dupixent in atopic dermatitis

Amber Tong

When Aslan Pharmaceuticals licensed the anti-IL13 receptor drug ASLAN004 from CSL, the plan was to hustle it through early-stage development then pass it off to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aslan doubles down on CSL drug, plots longshot rivalry with Dupixent in atopic dermatitis

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

DOGE terminates lease on FDA quality lab in St. Louis and 29 other sites

Misleading exhibit booth panel lands NJ drugmaker an untitled letter from FDA

Swiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and Biogen did the same

Trump blog: Some drugmakers cite FDA, NIH cuts as risk factors

China bans imports of Illumina's DNA sequencers following US tariffs

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Aslan dou­bles down on CSL drug, plots long­shot ri­val­ry with Dupix­ent in atopic der­mati­tis

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Aslan doubles down on CSL drug, plots longshot rivalry with Dupixent in atopic dermatitis